MetMab fails Phase III trial for NSCLC - Genentech
Genentech announced that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy. The study evaluated if onartuzumab (MetMab) in combination with Tarceva (erlotinib) helped people with previously treated, advanced Non-Small Cell Lung Cancer (NSCLC) whose tumours were identified as MET-positive live longer compared to Tarceva alone.
Overall adverse event rates were generally similar between the two groups. Data will be submitted for presentation at an upcoming medical meeting.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.